Key data
| Regulation | Commission Implementing Decision (EU) 2026/2566 of 19 November 2026 |
|---|---|
| Repealed norm | Implementing Decision (EU) 2026/1089 (medetomidine approval expiration extension) |
| Publication | 20 November 2026 |
| Entry into force | 19 November 2026 |
| Affected substance | Medetomidine as an active substance in biocides |
| Product type | Type 21 — antifouling products for vessel hulls |
| Regulatory framework | Regulation (EU) No 528/2012 of the European Parliament and of the Council |
| Affected parties | Manufacturers and distributors of antifouling biocides with medetomidine (marine and paint sector) |
| Category | European Regulation |
If your company manufactures, distributes or markets antifouling paints for vessel hulls containing medetomidine as an active substance, this decision affects you directly and immediately. Implementing Decision (EU) 2026/2566, published on 20 November 2026 and in force since 19 November 2026, repeals the previous Decision 2026/1089, which had delayed the expiration date of approval for this substance. With that extension no longer in effect, the regulatory clock returns to the original starting point.
What does this regulation establish?
The regulation establishes an immediate change to the regulatory status of medetomidine as an active substance in biocides of product type 21. To understand it, it is necessary to know the context of the two regulatory acts involved:
| Situation | Applicable norm | Effect on medetomidine |
|---|---|---|
| Before 2026/1089 | Regulation (EU) 528/2012 | Original approval expiration date in force |
| With Decision 2026/1089 | Implementing Decision (EU) 2026/1089 | The expiration date was delayed: medetomidine remained approved for longer |
| With Decision 2026/2566 (current) | Implementing Decision (EU) 2026/2566 | The extension is repealed: the original schedule of Regulation 528/2012 applies again |
In practical terms: the "extra window" that manufacturers had to continue marketing products with medetomidine has disappeared. Products that depended on that extended validity may have fallen outside the legal framework for marketing.
Regulation (EU) 528/2012 regulates the marketing and use of biocides in the European Union. Under this framework, an active substance can only be used in biocides if it is approved, and that approval has an expiration date. When the extension is repealed, products that depended on it must adjust to the original schedule or cease marketing.
Economic and operational impact
The operational and economic consequences of this decision are direct and materialize in three possible scenarios for affected companies:
- Product withdrawal from the market: Antifouling biocides containing medetomidine whose marketing depended on the repealed extension may no longer be legally marketable. This implies withdrawal costs, stock management and possible returns in the distribution chain.
- Product reformulation: Companies wishing to maintain an antifouling range will have to reformulate their paints by replacing medetomidine with other approved active substances, with the R&D, testing, registration and relaunch costs that this entails.
- Search for regulatory alternatives: In some cases, there may be the possibility of requesting new approval or using other routes provided for in Regulation 528/2012, but this requires time and technical and legal resources.
The impact is not only for manufacturers: distributors and marketers of these products must also verify the legal status of their catalog, as marketing a biocide with a non-approved active substance may constitute a breach of Regulation (EU) 528/2012.
Who does it affect?
- Manufacturers of antifouling paints for vessel hulls using medetomidine as an active substance.
- Distributors and marketers of product type 21 biocides (marine antifouling) with medetomidine in their composition.
- Companies in the marine sector that apply or supply surface treatment for vessels.
- Manufacturers of surface treatments that have included medetomidine in antifouling formulations for marine use.
- Regulatory advisors and compliance officers of companies in the chemical and marine sector that manage the portfolio of approved active substances.
Practical example
Imagine a Spanish company manufacturing marine paints that markets a line of antifouling products for recreational vessel hulls. One of its flagship products contains medetomidine as an active biocidal substance (product type 21).
When Decision 2026/1089 extended the expiration date of medetomidine approval, this company was able to continue manufacturing and selling that product without needing to reformulate it or withdraw stock. It planned its production and sales for the boating season assuming that the extension would remain in force.
With the entry into force of Decision 2026/2566 on 19 November 2026, that extension is repealed. The product may have lost its legal basis for marketing if the original approval of medetomidine had already expired. The company must now: verify the original expiration date of the approval, assess whether the product can continue to be sold, manage existing stock in the distribution channel and decide whether to reformulate the product or withdraw it from its catalog.
What should companies do now?
- Review the product portfolio: Identify all product type 21 biocides containing medetomidine as an active substance that were covered by the repealed extension.
- Verify the original approval schedule: Consult the expiration date of medetomidine approval under Regulation (EU) 528/2012 to determine whether products remain marketable.
- Evaluate stock in channel: Contact distributors to find out the volume of product with medetomidine in circulation and assess whether withdrawal is necessary.
- Initiate reformulation process or search for alternatives: If the product cannot continue to be marketed, start as soon as possible the reformulation process with approved active substances, given that registration and testing timelines are long.
- Consult with a regulatory advisor specialized in biocides: Biocide regulations under Regulation (EU) 528/2012 are technical and complex. A specialized advisor can precisely determine the concrete impact on each product and the available options.
- Communicate the change internally: Inform sales, marketing, production and logistics teams to prevent products that may have fallen outside the legal framework from continuing to be marketed or promoted.
Frequently asked questions
What is medetomidine and what is it used for in biocides?
Medetomidine is an active substance used in product type 21 biocides, that is, in antifouling paints and treatments for vessel hulls. Its function is to prevent the accumulation of marine organisms (algae, mollusks, etc.) on hulls, which improves performance and reduces fuel consumption of vessels.
What is the difference between Decision 2026/1089 and Decision 2026/2566?
Decision 2026/1089 had delayed the expiration date of medetomidine approval, granting an extension to manufacturers. Decision 2026/2566, published on 20 November 2026 and in force since 19 November 2026, repeals that extension, so the original approval schedule established by Regulation (EU) 528/2012 applies again.
Can antifouling products with medetomidine continue to be sold?
It depends on the original expiration date of medetomidine approval under Regulation (EU) 528/2012. With the extension repealed, products that depended on that extension may have lost their legal basis for marketing. It is essential to verify the regulatory status of each specific product with a biocide-specialized advisor.
What alternatives do antifouling paint manufacturers have?
Based on available information, affected companies have two main routes: reformulate their products by replacing medetomidine with other active substances approved under Regulation (EU) 528/2012, or explore other regulatory routes available in that regulation. Both options require time and technical and legal resources, so it is recommended to act as quickly as possible.
When did this decision enter into force and what timeline do companies have to adapt?
Implementing Decision (EU) 2026/2566 entered into force on 19 November 2026, one day before its official publication on 20 November 2026. The regulation does not establish an additional transitional period in the available information, so companies must review their situation immediately and without delay.
Official source
Consult full regulation at official source
Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=OJ:L_202602566